The mechanism underlying this elevation of hemoglobin is presumed to involve the enhancement of erythropoiesis in patients with normal kidney function.9 However, the effects of SGLT2 inhibition are unclear with regard to erythropoiesis in patients with chronic kidney disease. Here, SLC5A2 is linked to chronic kidney disease.